-
Rockwell Medical NASDAQ:RMTI Rockwell Medical is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU (ferric pyrophosphate citrate injection), are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
Location: 30142 Wixom Road, Michigan, 48393, United States | Website: www.rockwellmed.com | Industry: Surgical and Medical Instrument Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
1.43%
Insider Ownership
12.76%
Institutional Own.
25.64%
Qtr Updated
12/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Triferic (ferric pyrophosphate citrate) Details Anemia (hemodialysis dependent chronic kidney disease) | Approved Quarterly sales | |
Triferic® AVNU (ferric pyrophosphate citrate) Details Chronic kidney disease, Psoriasis, Kidney disease | Approved Quarterly sales |